Abstract
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. The molecular hallmark of CML is the BCR-ABL gene rearrangement, which typically is generated by the Philadelphia (Ph) chromosome. The Ph chromosome abnormality arises as a result of a mutated stem cell acquiring a balanced reciprocal translocation involving chromosomes 9 and 22. The chimeric BCR-ABL gene encodes an oncoprotein, termed p210BCR-ABL protein, which has an enhanced and deregulated tyrosine kinase activity. It is generally regarded as the principal molecular cause of the initial indolent stage (chronic phase) of CML and further proof for this notion came from the remarkable activity of the Abl kinase inhibitor, imatinib mesylate (formerly STI 571). Imatinib mesylate targets the autophosphorylation of the Abl kinase specifically and is not only effective in the majority of patients, its also relatively free of major adverse effects. Current experience suggests hematological responses in over 95% of patients in the chronic phase of CML, with about 70% achieving a major cytogenic response. The drug is only able to achieve complete molecular responses in a minority of patients and so may not affect molecular cure. It is noteworthy that patients in the more advanced phases of CML, which involves additional clonal events, also respond to imatinib mesylate but have a high incidence of treatment resistance and relapse.
Similar content being viewed by others
References
Fialkow PJ. Evidence for a multistep origin of chronic myeloid leukemia. Blood 1981; 58: 158–63
Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia [letter]. Science 1960; 132: 1497
Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–6
Goldman JM, Apperley JF, Jones LM, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202–7
Mughal TI, Yong A, Szydlo RM, et al. The probability of long-term leukaemia free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 2001; 115: 569–74
Melo JV. The diversity of the BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–84
Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4–10
Smith KM, Yacobi R, van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003; 12: 27–37
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 847–30
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–56
Anafi M, Gazit A, Zehavi A, et al. Tyrphostin-induced inhibition of p210 bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993; 82: 3524–9
Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR-ABL tyrosine kinase activity restores beta 1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998; 12: 1708–17
Okabe M, Uehara Y, Miyagishima T, et al. Effect of Herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein p210 bcr/abl and preferential inhibition on Ph-positive leukemia cell growth. Blood 1992; 80: 1330–8
Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myeloid leukemia. J Clin Invest 2000; 105: 3–7
Goldman JM, Melo JV. Targeting the BCR-ABL kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1084–86
Buchdunger E, Cioffi CL, Law N, et al. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45
Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 491–87
Okuda K, Weisberg E, Gilliland DG, et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440–8
Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938–42
Demetri GD, von Mehren M, Blancke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002; 347: 472–80
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 2003; 348: 1201–14
Goldman JM. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 2000; 355: 1031–2
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–42
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–52
Talpaz M, Silver RT, Druker B, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 2002; 99: 1928–37
Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–9
O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003; 348: 994–1004
Hughes TP, Kaeda J, Branford S, et al. On behalf of the IRIS study group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. New Engl J Med 2003; 349(15): 1423–32
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80
Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–9
Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemia cells through gene amplification. Blood 2000; 95: 1758–66
Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI5771 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498–505
Gambacorti-Passerini C, Barni R, le Courte P, et al. Role of alpha-1 acid glycoprotein in the in vivo resistance of human BCR-ABL leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641–50
Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–25
Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–8
Shannon KM. Resistance in the land of molecular therapeutics. Cancer Cell 2002; 2: 99–102
Von Bubnoff N, Schneller F, Peschel S, et al. BCR-ABL gene mutation in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487–91
Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61(12): 1765–74
Kantarjian HM, Talpaz M, O’Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myeloid leukemia. Blood 2003; 101: 473–5
Cortes J, Giles F, O’Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after of interferon-α. Blood 2003; 102: 83–6
Mughal TI, Goldman JM. Chronic myeloid leukaemia: STI571 magnifies the therapeutic dilemma. Eur J Cancer 2001; 37: 561–8
Goldman JM, Druker B. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–42
Acknowledgements
No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mughal, T.I., Goldman, J.M. Chronic Myeloid Leukemia. Am J Cancer 2, 305–311 (2003). https://doi.org/10.2165/00024669-200302050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024669-200302050-00001